DK1527047T3 - 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amin)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-monoethansulphonat og anvendelse deraf som en farmaceutisk sammensætning - Google Patents

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amin)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-monoethansulphonat og anvendelse deraf som en farmaceutisk sammensætning

Info

Publication number
DK1527047T3
DK1527047T3 DK03766212.9T DK03766212T DK1527047T3 DK 1527047 T3 DK1527047 T3 DK 1527047T3 DK 03766212 T DK03766212 T DK 03766212T DK 1527047 T3 DK1527047 T3 DK 1527047T3
Authority
DK
Denmark
Prior art keywords
methyl
indolinone
methylcarbonyl
anilino
piperazin
Prior art date
Application number
DK03766212.9T
Other languages
English (en)
Inventor
Thomas Bock
Gerald Juergen Roth
Peter Sieger
Guenter Linz
Werner Rall
Frank Hilberg
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1527047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1527047T3 publication Critical patent/DK1527047T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK03766212.9T 2002-07-24 2003-07-18 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amin)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-monoethansulphonat og anvendelse deraf som en farmaceutisk sammensætning DK1527047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
PCT/EP2003/007822 WO2004013099A1 (en) 2002-07-24 2003-07-18 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK1527047T3 true DK1527047T3 (da) 2012-07-16

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03766212.9T DK1527047T3 (da) 2002-07-24 2003-07-18 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amin)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-monoethansulphonat og anvendelse deraf som en farmaceutisk sammensætning

Country Status (35)

Country Link
US (2) US7119093B2 (da)
EP (2) EP1527047B1 (da)
JP (1) JP5039279B2 (da)
KR (1) KR101145691B1 (da)
CN (1) CN100351235C (da)
AR (2) AR040662A1 (da)
AT (1) ATE551322T1 (da)
AU (1) AU2003254376B2 (da)
BR (1) BRPI0312811B8 (da)
CA (1) CA2493310C (da)
CY (1) CY1112916T1 (da)
DE (1) DE10233500A1 (da)
DK (1) DK1527047T3 (da)
EA (1) EA008684B1 (da)
EC (1) ECSP055571A (da)
EG (1) EG24562A (da)
ES (1) ES2384968T3 (da)
HR (1) HRP20050070B1 (da)
IL (2) IL166405A0 (da)
ME (1) ME00353B (da)
MX (1) MXPA04012785A (da)
MY (1) MY136883A (da)
NO (1) NO330486B1 (da)
NZ (1) NZ538367A (da)
PE (1) PE20040704A1 (da)
PL (1) PL223758B1 (da)
PT (1) PT1527047E (da)
RS (1) RS52283B (da)
SA (1) SA03240446B1 (da)
SI (1) SI1527047T1 (da)
TW (1) TWI285635B (da)
UA (1) UA78352C2 (da)
UY (1) UY27904A1 (da)
WO (1) WO2004013099A1 (da)
ZA (1) ZA200409814B (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
CA2687909C (en) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
RU2525114C2 (ru) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
UY31506A1 (es) * 2007-12-03 2009-08-03 Derivados de indolinona y procedimiento para su preparacion
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
UA104590C2 (ru) * 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
ME02273B (me) * 2008-06-06 2016-02-20 Boehringer Ingelheim Int Farmaceutska kombinacija
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
JP2012526767A (ja) * 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌及び線維性疾患の処置における新規な併用療法
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
WO2014012859A1 (en) 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) * 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) * 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
US20190160054A1 (en) 2016-04-13 2019-05-30 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017198202A1 (zh) * 2016-05-19 2017-11-23 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
WO2017203027A1 (en) 2016-05-27 2017-11-30 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
EP3515444A4 (en) 2016-09-26 2020-06-03 Reyoung (Suzhou) Biology Science & Technology Co., Ltd COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
WO2018160967A1 (en) * 2017-03-02 2018-09-07 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN110072849A (zh) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited Process for the preparation of nintedanib
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP7382317B2 (ja) 2017-11-17 2023-11-16 フェルミオン オサケ ユキチュア ニンテダニブを製造するための中間体として公知の２－インドリノン誘導体の合成
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
EP3841090A4 (en) 2018-08-22 2022-10-19 Avalyn Pharma Inc. SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
US20230181582A1 (en) 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
CA3191013A1 (en) * 2020-08-07 2022-02-10 Bdr Lifesciences Private Limited An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
US20250161250A1 (en) 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en) 2023-12-27 2025-07-02 Faran S.A. Oral suspensions comprising nintedanib esylate
KR20250118711A (ko) 2024-01-30 2025-08-06 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 생체이용률이 개선된 경구투여용 제제
WO2025261988A1 (fr) 2024-06-17 2025-12-26 Assistance Publique Hopitaux De Paris Utilisation de nintédanib pour le traitement de la maladie de castleman

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001014330A2 (en) * 1999-08-23 2001-03-01 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
BRPI0312811A8 (pt) 2019-01-02
CA2493310C (en) 2011-01-18
PT1527047E (pt) 2012-06-28
AU2003254376A1 (en) 2004-02-23
ES2384968T3 (es) 2012-07-16
CY1112916T1 (el) 2016-04-13
ME00353B (me) 2011-10-10
TWI285635B (en) 2007-08-21
JP2005535684A (ja) 2005-11-24
PL223758B1 (pl) 2016-10-31
ZA200409814B (en) 2006-02-22
US7119093B2 (en) 2006-10-10
DE10233500A1 (de) 2004-02-19
AR040662A1 (es) 2005-04-13
EP1527047B1 (en) 2012-03-28
UY27904A1 (es) 2004-02-27
NZ538367A (en) 2008-01-31
EP1527047A1 (en) 2005-05-04
US20060258681A1 (en) 2006-11-16
EG24562A (en) 2009-10-25
US20040176392A1 (en) 2004-09-09
MEP53708A (en) 2011-05-10
EP2386543A1 (en) 2011-11-16
JP5039279B2 (ja) 2012-10-03
PE20040704A1 (es) 2004-11-29
TW200409754A (en) 2004-06-16
SA03240446B1 (ar) 2007-07-31
RS20050046A (sr) 2007-09-21
AU2003254376B2 (en) 2010-06-17
CN100351235C (zh) 2007-11-28
IL166405A (en) 2009-11-18
BRPI0312811B1 (pt) 2019-03-12
SI1527047T1 (sl) 2012-07-31
MXPA04012785A (es) 2005-06-08
RS52283B (sr) 2012-10-31
EA200500146A1 (ru) 2005-08-25
IL166405A0 (en) 2006-01-15
MY136883A (en) 2008-11-28
BRPI0312811B8 (pt) 2021-05-25
PL372996A1 (en) 2005-08-08
WO2004013099A1 (en) 2004-02-12
ECSP055571A (es) 2005-04-18
ATE551322T1 (de) 2012-04-15
KR20050042139A (ko) 2005-05-04
HRP20050070B1 (hr) 2013-09-30
HRP20050070A2 (en) 2005-12-31
KR101145691B1 (ko) 2012-05-25
AR094217A2 (es) 2015-07-15
CN1671660A (zh) 2005-09-21
HK1078851A1 (zh) 2006-03-24
BR0312811A (pt) 2005-04-19
CA2493310A1 (en) 2004-02-12
UA78352C2 (uk) 2007-03-15
NO20050985L (no) 2005-02-23
NO330486B1 (no) 2011-04-26
EA008684B1 (ru) 2007-06-29

Similar Documents

Publication Publication Date Title
DK1527047T3 (da) 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amin)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-monoethansulphonat og anvendelse deraf som en farmaceutisk sammensætning
NO20044095L (no) 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
DK1448535T3 (da) Benzamid og heteroarylamid som P2X7-receptor antagonister
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20034187D0 (no) Nye spirotricykliske derivater og anvendelse derav som fosfodiesterase-7 inhibitorer
NO20033099L (no) N-(fenylsulfonyl)glycin-derivater og deres terapeutiske anvendelse
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK2045241T3 (da) Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20043904L (no) Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens
DK1527050T3 (da) Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20034324D0 (no) Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DK1484970T3 (da) Benzamider og sammensætninger omfattende benzamider til anvendelse som fungicider
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK1558595T3 (da) Piperazinyl- og diazapanylbenzamider og -benzthioamider
NO20043580L (no) Quinazolinonderivater og deres bruk som CB agonister
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
NO20030382L (no) Nye indolderivater og deres anvendelse som medikamenter
NO20025504L (no) Nye tiokromanderivater og anvendelse derav som trombininhibitorer